Vincerx Pharma, Inc. VINC
At closeFeb 5, 2026, 4:00 PM EST
After hours · Feb 5, 4:00 PM ET
- YTD
- 0.00%
- 1 year
- -75.00%
- Market cap
- 68.05K
- EPS (ttm)
- -9.05
- Shares out
- 33.65M
- Forward P/E
- -0.30
- YTD return
- 0.00%
- 1-year return
- -75.00%
- Volume
- 22
- Avg volume
- 665
- Open
- 0.0053
- Previous close
- 0.013
- Day's range
- 0.0053 – 0.0053
- 52-week range
- 0.005 – 0.026
- Price target
- 6.00 (+46053.8%)
- Earnings date
- Aug 8, 2024
1Y +0.0100 (+200.00%)
Key statistics
- Enterprise value
- -1.50M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -19.56M
- Total cash
- 10.09M
- Total debt
- 1.64M
- Return on equity
- -211.86%
- Short % of float
- 2.47%
- 50-day average
- 0.29914
- 200-day average
- 1.16
Analyst view
- Target (low)
- 2.00
- Target (mean)
- 6.00
- Target (high)
- 10.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.17 | -0.17 | 0.00 | 0.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | -0.05 | +0.12 | +70.59% |
| May 14, 2024 | Mar 1, 2024 | -0.26 | -0.34 | -0.08 | -30.77% |
| May 14, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -0.42 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2024 | Leerink Partners | main | Outperform | Outperform |
| Apr 9, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Apr 1, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 17, 2022 | Chardan Capital | main | — | Buy |
| Aug 12, 2022 | SVB Leerink | main | — | Outperform |
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vincerx.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - 12 Health Care Stocks Moving In Monday's Intraday Session
Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert 
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on VINC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAMDY AHMED | President | Purchase | Aug 9, 2023 | 0 |
| IZUMI RAQUEL E. | President | Purchase | Aug 9, 2023 | 0 |
| SEELENBERGER ALEXANDER A. | Officer | Purchase | Aug 10, 2023 | 30,280 |
| THOMAS TOM C | President | Purchase | Aug 9, 2023 | 229,935 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.04% | 2,704,000 | 534.85K | Sep 29, 2024 |
| Prosight Management, Lp | 6.56% | 2,206,505 | 436.45K | Sep 29, 2024 |
| Sage Rhino Capital LLC | 5.06% | 1,703,413 | 336.94K | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 2.65% | 891,719 | 176.38K | Sep 29, 2024 |
| Point72 Asset Management, L.P. | 2.00% | 674,193 | 133.35K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 1.88% | 631,424 | 124.89K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.01% | 341,070 | 67.46K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.83% | 280,416 | 55.47K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 145,814 | 28.84K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 34,436 | 6.81K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 30,971 | 6.13K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,662 | 526 | Oct 30, 2024 |